Graphical Abstract Highlights d PRMT6 is downregulated in HCC and correlates negatively with aggressive HCC d PRMT6 silencing drives cancer stemness in vitro and patientderived organoids d PRMT6 binds to CRAF, methylates it, and interferes with its RAS/RAF binding d Methylation of CRAF regulates MEK/ERK-mediated cancer stemness in HCC Correspondence stefma@hku.hk In Brief RAS/RAF/MEK/ERK pathway signaling is known to be frequently activated in cancers, in which it regulates cell growth, malignant transformation, drug resistance, and stemness. Using hepatocellular carcinoma as a model system, Chan et al. describe a mechanism by which this oncogenic signaling pathway is regulated by PRMT6 at the post-translational level via arginine methylation.
SUMMARY
Arginine methylation is a post-translational modification that plays pivotal roles in signal transduction and gene transcription during cell fate determination. We found protein methyltransferase 6 (PRMT6) to be frequently downregulated in hepatocellular carcinoma (HCC) and its expression to negatively correlate with aggressive cancer features in HCC patients. Silencing of PRMT6 promoted the tumor-initiating, metastasis, and therapy resistance potential of HCC cell lines and patient-derived organoids. Consistently, loss of PRMT6 expression aggravated liver tumorigenesis in a chemical-induced HCC PRMT6 knockout (PRMT6 À/À ) mouse model. Integrated transcriptome and protein-protein interaction studies revealed an enrichment of genes implicated in RAS signaling and showed that PRMT6 interacted with CRAF on arginine 100, which decreased its RAS binding potential and altered its downstream MEK/ERK signaling. Our work describes a critical repressive function for PRMT6 in maintenance of HCC cells by regulating RAS binding and MEK/ERK signaling via methylation of CRAF on arginine 100.
INTRODUCTION
Post-translational modifications lie at the heart of the fields of epigenetics and signal transduction. Arginine methylation is a common post-translational modification functioning as an epigenetic machinery of transcription and playing key roles in mRNA translation, cell signaling, and cell fate decision. In mammals, arginine methylation is carried out by protein arginine methyltransferases (PRMTs) (Bedford and Clarke, 2009; Blanc and Richard, 2017) . Recent studies have defined physiological roles of PRMTs, linking them to diseases such as cancer and metabolic disorders. PRMT6 belongs to the type I PRMT enzyme family, responsible for catalyzing the asymmetric dimethylation of arginine (ADMA) residues on proteins (Blanc and Richard, 2017) . It was initially identified to modify GAR motifs and subsequently found to target histones, although non-histone targets have also been described (Frankel et al., 2002; Guccione et al., 2007; Iberg et al., 2008; Hyllus et al., 2007; Di Lorenzo et al., 2014) . The role of PRMT6 in normal and cancer cell remains controversial. It has been reported to function as both a transcriptional repressor and activator and be overexpressed and repressed in different tumor types. Reduced PRMT6 expression has been reported in melanoma (Limm et al., 2013) , while overexpression of PRMT6 is detected in cancers of the bladder, lung, cervix, breast, and prostate (Almeida-Rios et al., 2016; Yoshimatsu et al., 2011) . Importantly, studies on PRMT6 to date have only been focused on its function in the nucleus. The biological significance and the key target proteins of PRMT6 in human cancer remains elusive.
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancer types in the world. Resection and transplantation is remedial for early-stage HCC. Yet because most patients are diagnosed at an advanced stage, most HCCs are inoperable. Chemotherapy and molecular targeted therapies are available for advanced HCC patients, but their effects have shown only modest results. HCC tumors are heterogeneous and contain cells that sit at the apex of cellular hierarchies with stem-like properties. These HCC stem-like cells can self-renew, are resistant to conventional therapy, and can contribute to tumor recurrence (Yamashita and Wang, 2013) . Treatment of HCC with chemotherapy has been found to select for the outgrowth of therapy-resistant stem-like cancer cells that contribute to tumor recurrence and poor therapeutic outcome (Visvader and Lindeman, 2012) . This underscores the need for a better understanding of the molecular mechanisms driving stemness in HCC cells in hope to discover features that may render HCC cells with stem-like properties more susceptible to selective therapeutic intervention.
RAF kinases are well-known oncoproteins that play a critical role in promoting cancer through activation of the MEK/ERK signaling cascade (Lavoie and Therrien, 2015) . In recent years, MEK/ERK activation has been extensively reported to be essential for mediating the self-renewal capacity and drugresistant properties of HCC cells, leading to poor patient survival. Activation of the RAS/RAF/MEK/ERK cascade is observed in 50%-100% of HCC tumors (Ito et al., 1998 ), yet activating mutations of RAS/RAF are infrequent, with downregulation of inhibitory regulators of the pathway being the more common alternative mechanism leading to activation of MEK/ ERK. Although the presence of repressive elements in RAF has been long recognized, they cannot account for all MEK/ ERK activations in HCC, while post-translational modifications other than phosphorylation that control RAF kinase activity remains elusive. A broader understanding of how negative regulatory effectors on this signaling pathway are deregulated in HCC is important for future development of anti-cancer strategies. Our present study uncovered the clinical significance and functional role of PRMT6 in mediating HCC stemness and dissected the molecular mechanism by which PRMT6 contributes to these effects via interaction and methylation of CRAF on arginine 100.
RESULTS

PRMT6 Is Weakly Expressed and Negatively Correlated with Aggressive Cancer Features in HCC Patients
We investigated PRMT6 mRNA expression in 77 primary HCC and matched non-tumor liver tissues using qPCR. PRMT6 downregulation of R2-fold was displayed in 55.8% (43 of 77) of the HCC specimens compared with non-tumor specimens ( Figures  1A and 1B ). Analysis of a publicly available dataset (The Cancer Genome Atlas [TCGA], Liver Cancer) also showed PRMT6 downregulation in HCC compared with normal liver samples (Figure 1C) . These observations were further validated by immunohistochemistry (IHC) in a separate cohort consisting of 83 primary HCC and adjacent non-tumor tissue (Figures 1D and 1E) , in which PRMT6 downregulation in HCC was significantly associated with older age (p = 0.025), presence of vascular invasion (p = 0.035), intraoperative rupture (p = 0.049), and a trend toward absent or incomplete tumor encapsulation (p = 0.053) (Table S1 ). Different PRMT6 antibodies were used for IHC, including one validated by the Human Protein Atlas, to provide further confidence to our work ( Figure S1 ). Expression of PRMT6 was also tested in HCC cell lines for selecting cell lines for subsequent functional studies ( Figure 1F ).
PRMT6 Negatively Regulates Cancer and Stem Cell-like Properties in HCC
To determine the pathological role of PRMT6 in HCC, we ablated PRMT6 expression in BEL7402 with two distinct short hairpin RNAs (shRNAs) (933 and 956) and stably overexpressed PRMT6 in Huh7 and/or MHCC97L cells ( Figures S2A-S2C ). Knockdown of PRMT6 resulted in attenuated PRMT6 expression but not other members of the PRMT family, providing evidence that the effects observed are due solely to PRMT6 ( Figure S2D ). PRMT6 depletion led to potentiated ability of the cells to migrate, invade, and resist cisplatin, 5-fluorouracil, and sorafenib. Conversely, stable PRMT6 overexpression in Huh7 cells resulted in opposing effects (Figures 2A and 2B) . We extended our studies in vivo, in which HCC cells with PRMT6 manipulated were injected subcutaneously or orthotopically into nude mice to determine the role of PRMT6 in HCC formation. Overexpression of PRMT6 resulted in a profound decrease in the ability of cells to initiate tumor growth, while knockdown of PRMT6 led to a marked induction (Figures 2C and 2D) . We also examined the role of PRMT6 in HCC metastasis in vivo by orthotopic implantation of HCC cells into the livers of immunodeficient mice. Because BEL7402 and Huh7 cells are known to be unable to form metastases following intrahepatic injection, luciferaselabeled MHCC97L cells overexpressing empty vector (EV) or PRMT6 were used instead. Extrahepatic lung metastasis was monitored by ex vivo bioluminescence imaging, and metastasis was detected in four of six mice in the EV group, in contrast to only two of six mice in the PRMT6 overexpression group (Figure 2E) , with a faster metastasis onset. Altered ability of the cells to metastasize was also evident by a decreased number of tumor nodules present in the lung of mice injected with PRMT6 overexpressing cells ( Figure 2E ). PRMT6 negatively regulated not only aggressive cancer features but also stem-like properties of HCC. HCC cells with PRMT6 overexpressed displayed attenuated abilities to induce oncosphere formation in serial passages ( Figure 3A ), as well as reduced expression of CD133 HCC stem-like subpopulation ( Figure 3B ) and pluripotency markers SOX2 and NANOG (Figure 3C) . Knockdown of PRMT6 resulted in an opposing trend (Figures 3A and 3C) . Note expression of other liver cancer stem cell (CSC) markers such as CD24 and CD90 were not found to be altered following PRMT6 expression modulation (Figure S2F) . To assess the degree to which PRMT6 supports growth and maintenance of CD133 + HCC stem-like cells, Huh7 cells overexpressing EV (PRMT6 low ) or PRMT6 (PRMT6 high ) were sorted into CD133 + and CD133 À subsets and injected into NOD/SCID mice at limiting dilutions. Mice injected with CD133 + PRMT6 low cells showed increased tumor incidence, expedited tumor latency, and a higher frequency of tumor-initi-ating cells compared with other subgroups ( Figure 3D ). Selfrenewal ability of cells was then examined by serial transplantation of primary xenografts into secondary mouse recipients. Single cells isolated from the four groups were resorted into CD133 + and CD133 À subsets and injected at limiting dilutions. CD133 + PRMT6 low cells displayed further expedited tumor latency in their ability to reconstitute tumor formation in secondary transplantations. Statistically, HCC cells with low PRMT6 showed a significantly worse tumor-free survival compared with HCC cells with high PRMT6 expression (CD133 + PRMT6 low versus CD133 + PRMT6 high ) in serial transplantations ( Figure 3D ). Note that because BEL7402 cells do not express any endogenous CD133, we were unable to analyze change in CD133 expression and sort CD133 subpopulation for in vivo assays as we did for Huh7. Note that similar results were also achieved in BEL7402 cells with PRMT6 knocked out by CRISPR/Cas9, suggesting that the observed effects are due solely to PRMT6 and not other members of the PRMT family ( Figure S2E ).
The Catalytically Active Domain of PRMT6 Is Functionally Important in Contributing Augmented Cancer Stemness Properties in HCC Lentiviral-based knockdown and overexpression of PRMT6 led to a concomitant respective decrease and increase of ADMA ( Figure 4A ), suggesting that the global arginine methyltransferase activity of these cells was altered. To examine whether PRMT6 confers altered cancer stemness properties in HCC through this enzymatic activity, we performed similar functional studies with wild-type PRMT6 or catalytic methyltransferase inactive mutant PRMT6 VLD:KLA (Neault et al., 2012) overexpressed in BEL7402 HCC cells ( Figure 4B ). Ectopic overexpression of wild-type and catalytic inactive PRMT6 mutant displayed predominant cytoplasmic PRMT6 localization ( Figure S3 ). Functionally, wild-type PRMT6 overexpression conferred the ability of HCC cells to diminish migration, invasion, and oncosphere formation ( Figures 4C-4E ). Furthermore, it led to attenuated ability of the cells to resist cisplatin, 5-fluorouracil, and sorafenib as well as a reduced expression of SOX2 ( Figures 4C-4G ). Overexpression of wild-type PRMT6 also resulted in a decrease in the ability of the cells to initiate tumors in vivo ( Figure 4H ). In contrast, a catalytic methyltransferase inactive mutant of PRMT6 was unable to confer such functional phenotype.
PRMT6 Interacts Directly with CRAF
Contrary to what is reported in the literature for other tumor types, we found modulation of PRMT6 to not play a very significant or consistent role in H3R2 methylation, at least in the context of HCC, as evidenced by both H3R2me2a expression and chromatin immunoprecipitation (ChIP)-qPCR experiments on promoter regions of p21, p27, and p57, previously reported to be regulated by H3R2me2a, coupled with expression analysis of p21, p27, and p57 extracted from our microarray data (Figure S4) . More importantly, PRMT6 is predominantly expressed in the cytoplasm of HCC cells ( Figure S5 ). To ensure that our observation was HCC specific, we performed the same immunofluorescence experiment using two PRMT6 antibodies and with MCF7 breast cancer cells, which have previously been reported to express only nuclear PRMT6 (Hyllus et al., 2007) , as a positive control, with findings in support of our hypothesis (Figure S5) . To elucidate the underlying mechanism of PRMT6 in the regulation of HCC stem-like cells, we used an integrative approach whereby we sought to identify both downstream altered genes and potential binding partners of PRMT6, hoping to identify members of the pathway that are regulated via arginine methylation. mRNA profiling of HCC cells with or without PRMT6 stably suppressed identified significantly deregulated genes that closely associated with RAS signaling and aggressive cancer phenotypes, including epithelial-mesenchymal transition (Figures 5A and S6; Table S2 ). Tandem affinity purification coupled with mass spectrometry (TAP-MS) analysis of PRMT6 immunoprecipitates identified a list of PRMT6-interacting proteins. Through integrating mRNA profiling and TAP-MS analysis, we shortlisted 11 RAS signaling-related proteins that potentially bind to PRMT6, including RAF1/CRAF (Table S3 ). Downstream signaling of CRAF, namely, MEK/ERK, has previously been shown by us and others to promote stem cell-like properties in HCC, and thus we hypothesized that PRMT6 regulates HCC stem-like cell via binding to CRAF and altering downstream MEK/ERK signaling. To test our hypothesis, we first confirmed the interaction between PRMT6 and CRAF by reciprocal immunoprecipitations in 293T and HCC cells, using both tagged and endogenous proteins ( Figure 5B ). Following confirmation of their binding, we then examined for the presence of PRMT6-mediated enzymatic methylation of CRAF by in vivo methylation assay. Levels of ADMA were drastically increased when PRMT6 plasmid was co-transfected relative to EV control ( Figure 5C , left). To further provide direct evidence in support of CRAF as a specific PRMT6 substrate, in vitro methylation assay was then carried out, alongside a glycine-arginine-rich (GAR) sequence as a positive control. In the presence of PRMT6, methylation of CRAF was dramatically potentiated ( Figure 5C , middle and right).
PRMT6 Methylates CRAF on Arginine 100 Residue
An in silico analysis of the CRAF protein sequence by PMeS prediction revealed seven arginine residues that could be potentially methylated (Table S4 ). To identify which arginine residues are methylated by PRMT6, we created full-length and multiple truncated mutants of CRAF ( Figure 5D ). When CRAF full-length (FL) and truncated mutants (D1-D3) were co-transfected with PRMT6 into 293T cells for in vivo methylation assay, ADMA at the predicted size (red arrows) could be detected in FL CRAF as well as D1 and D3 truncated CRAF, where arginine residues 89 and 100 are present. In contrast, the predicted ADMA band could not be detected in D2 truncated CRAF, where arginine 89 and 100 residues are deleted ( Figure 5E , white arrow). These observations indicated that arginine 89 and 100 in CRAF were the potential targets of PRMT6. In vivo and in vitro methylation assays using site-directed R89K and R100K CRAF mutants showed that only R100 was specifically methylated by PRMT6 ( Figure 5F ). This was further confirmed by in vitro methylation assays using peptide overlying nine amino acids around R100 residue (CAVFRLLHE) or with R/K substitution (CAVFKLLHE), (D) Images of xenograft tumors (red arrows) formed in NOD/SCID mice injected subcutaneously with CD133 + PRMT6 low , CD133 + PRMT6 high , CD133 À PRMT6 low , and CD133 -PRMT6 high cells isolated from Huh7 cells in primary passage (picture representative of 10,000 cells injected). Kaplan-Meier curves showing percentage of tumor-free survival of the annotated groups of primary and secondary recipient mice. n = 8. Engraftment rates, average tumor latency, and tumorinitiating frequency of CD133 + and CD133 À subsets with or without PRMT6 overexpressed in Huh7 cells. EV, empty vector control; NTC, non-target control; OE, overexpression; TIC, tumor-initiating cells. Data are representative of two or more independent experiments. Bars and error represent mean ± SD of replicate measurements.
showing methyl group incorporation in R100 peptide only (Figure 5G) . On further analysis, we also found PRMT6 to similarly bind to other RAF family members that show high homology to CRAF, including ARAF and BRAF. Arginine residues were also predicted on ARAF and BRAF (Table S4) , with R100 consistently corresponding to the 45th amino acid residue within the RAS binding domain (RBD) across all three human RAF proteins and locating within a highly conserved sequence motif consisting of six amino acids (Tables S5 and S6 ), suggesting the critical role of this arginine residue. The data serve as proof of concept that PRMT6 may potentially methylate ARAF and BRAF at the same arginine residue to elicit similar downstream effects, as in CRAF. ( Figure 6E ). The observation that binding between RAS and CRAF with R100K mutation was not affected by shPRMT6 also confirmed the importance of R100 residue methylation (Figure 6F ). To show that PRMT6-mediated methylation regulates RAS/RAF binding, GST-CRAF with or without in vitro methylation was subsequently incubated with MBP-RAS for RAS binding assay. Upon PRMT6 in vitro methylation, RAS binding affinity was diminished in CRAF wild-type (WT) but not in CRAF R100K mutant ( Figure 6G ).
Loss of PRMT6 Expression Aggravates Liver
Tumorigenesis in a DEN+CCL 4 HCC-Induced PRMT6 Knockout Mouse Model Next, we extended our studies with PRMT6 knockout (PRMT6 À/À ) mice (Neault et al., 2012) . WT C57BL/6J and PRMT6 À/À mice were subjected to DEN+CCl 4 treatment, for induction of a fibrosis/inflammation-associated HCC that closely mimics the disease in human. PRMT6 À/À mice developed bigger HCC tumors than WT mice and a trend toward higher liver over body weight in PRMT6 À/À mice ( Figures 7A and 7B) . H&E staining revealed larger areas of tumors in PRMT6 À/À mice compared with controls, while IHC also showed absence of PRMT6, concomitant with stronger expression of pERK1/2 in the PRMT6 À/À mice compared with WT mice (Figure 7C ). extended in a setting that more closely mimics the real clinical situation, we established non-tumor liver and HCC patientderived three-dimensional (3D) organoids, with or without PRMT6 stably altered ( Figure 7D ). Note that our organoids have been thoroughly characterized at both molecular and phenotypic levels, with comparison made against the original non-tumor liver and HCC tissue samples (unpublished data). Knockdown of PRMT6 in non-tumor liver organoids significantly enhanced the abilities of the cells to resist both chemo-and molecular-targeted drugs, while overexpression of PRMT6 in HCC organoids attenuated the cells ability to migrate, invade, and form oncospheres ( Figures 7E and 7F ). Consistently, alteration in expression of CD133, NANOG, SOX2, and p-ERK1/2 was also observed ( Figure 7D ).
PRMT6-Dependent
DISCUSSION
Arginine methylation is a post-translational modification as common as phosphorylation and ubiquitination (Larsen et al., 2016) . The methylation of arginine residues is catalyzed primarily by PRMT enzymes, which includes PRMT6. Previous studies found PRMT6 to be predominantly nuclear and methylates arginineand glycine-rich (RGG/RG) motifs, though it has also been shown to methylate arginines neighboring charged residues, as observed with HIV Tat (Boulanger et al., 2005) . PRMT6-mediated methylation is generally associated with transcriptional repression by generating H3R2me2a (Guccione et al., 2007; Iberg et al., 2008; Hyllus et al., 2007; Di Lorenzo et al., 2014) , although it has also been reported that PRMT6 functions as a co-activator of nuclear receptors (Harrison et al., 2010) . PRMT6-mediated histone methylation also regulates poised chromatin to maintain the balance between pluripotency and differentiation . In the normal liver, PRMT6 promotes fasting-induced transcriptional activation of gluconeogenesis involving CRTC2 (Han et al., 2014) . Earlier studies have suggested the regulatory function of PRMT6 in cellular proliferation, senescence, and cell cycle progression (Kleinschmidt et al., 2012; Phalke et al., 2012; Stein et al., 2012) , while one very recent study reported on the role of PRMT6 in regulating DNA methylation and contributing to global DNA hypomethylation in cancers of the breast, prostate, colon, lung, nerve, and bone (Veland et al., 2017 ). Yet the disease-associated expression and function of PRMT6 in HCC have remained unclear. Our present study finds PRMT6 to play a critical role in negatively regulating the maintenance of stemness feature of HCC cells. It is interesting to also note that, consistent with the study by Veland et al. (2017) , our pilot data also suggest that arginine methyltransferase activity of PRMT6 results in DNA hypomethylation in HCC cells, as evident by 5mc immunofluorescence staining. Specifically, global DNA hypomethylation was observed in cells overexpressing WT PRMT6 but not the catalytic inactive PRMT6 mutant (data not shown). However, whether this observed methylation change is dependent on H3R2me2a remains to be elucidated. The upstream regulator of PRMT6 has not been defined. PRMT6 lies on chromosome 1p13.3, which has previously been reported to be frequently detected in HCC (Guan et al., 2000) . Thus, we also did some preliminary analysis on data ex-tracted from TCGA Liver Hepatocellular Carcinoma (LIHC) to examine if gene copy number loss or deletion contributes to the frequent downregulation of PRMT6 in HCC. We found PRMT6 gene copy number loss or deletion to be detected in 23.5% of 370 HCC samples and that the loss was positively correlated with decreased PRMT6 mRNA expression (data not shown). In addition, we also identified a CpG island in the promoter region of PRMT6 and also carried out pilot studies to test if 5-aza-2 0 -deoxycytidine (5-aza) and trichostatin A (TSA) combination treatment would lead to re-expression of PRMT6 in low-PRMT6-expressing HCC cells. Treatment with 5-aza and TSA resulted in only a slight 2-fold to 3-fold re-expression of PRMT6 (data not shown). Our data on the underlying mechanisms contributing to PRMT6 downregulation in HCC remain inconclusive, and further study is warranted. Whether PRMT6 is regulated by microRNAs (miRNAs) or other regulatory proteins can also be further explored.
PRMT6-mediated H3R2me2a of promoter DNA leads to epigenetic silencing of transcription of the cell cycle inhibitor p21 as well as the angiogenic inhibitor TSP1 (Phalke et al., 2012; Michaud-Levesque and Richard, 2009; Nakakido et al., 2015; Kim et al., 2013) . It remains to be elucidated whether PRMT6 act as a chromatin modifier in HCC. Our pilot data are at the moment inconclusive, as evidenced by enhanced methylation at the promoter regions of p21, p27, and p57 by H3R2me2a, despite inconsistent p21, p27, and p57 expression change and H3R2me2a expression being unaltered when PRMT6 is modulated ( Figure S4 ). But more interestingly, we observed a predominant cytoplasmic localization of PRMT6 in normal liver and HCC cells, rather than its well-recognized nuclear localization. This observation was validated with two PRMT6 antibodies, including one that is validated by the Human Protein Atlas. Why PRMT6 is predominantly localized in the cytoplasm of liver and HCC cells remains to be answered, but in the past, a number of PRMTs, such as PRMT1 and PRMT5, have also been found to be capable of shuttling between the nucleus and cytoplasm (Herrmann et al., 2005; Herrmann and Fackelmayer, 2009; Gu et al., 2012) . For instance, presence of nuclear exclusion signals (NESs) is found responsible for the cytoplasmic localization of PRMT5 in prostate pre-malignant and cancer tissues (Gu et al., 2012) . It will be interesting to explore whether liver and HCC cells also contain such NES in the PRMT6 protein.
Although non-histone proteins, including GPS2, CRTC2, Tat, HMGA1a, and PRMT6 itself, are known substrates of PRMT6 (Boulanger et al., 2005; Han et al., 2014; Singhroy et al., 2013; Huang et al., 2015) , cytoplasmic proteins specifically methylated by PRMT6 have not been reported. Through an integrative approach, adopting both transcriptome and protein-protein interaction studies, CRAF was identified as one of the cytoplasmic interacting partners of PRMT6. We went on to validate CRAF as a functional substrate of PRMT6 and identified R100 as the specific arginine residue on CRAF targeted by PRMT6. Methylation of CRAF on arginine 100 in the RBD would result in its altered RAS binding potential and thus modulation of the downstream MEK/ERK signaling cascade. Collectively, we found PRMT6 downregulation in HCC to mediate cancer stemness properties via decreased interaction with CRAF and thus reduced methylation on CRAF arginine 100, thereby resulting in its altered RAS binding potential and subsequent activation of downstream MEK/ERK signaling.
Targeting MEK/ERK signaling and in vivo target gene activation of PRMT6 expression in HCC represents a promising anti-cancer stemness therapeutic strategy. In fact, there are a number of MEK/ERK inhibitors available on the market that are either approved for use in patients or under clinical evaluation, including the U.S. Food and Drug Administration (FDA)-approved MEK inhibitors trametinib (GSK1120212) and cobimetinib (GDC-0973, XL518) and MEK/ERK inhibitors in clinical trials, including binimetinib (MEK162), selumetinib, PD-325901, SCH772984, and others. There are now ample data to show that patients respond only partially to single-drug treatments against the MEK/ERK pathways and that MEK/ERK inhibitors would be best if given in combination with other drugs, instead of as a single agent. Our present study revealed that the downregulation of PRMT6 in HCC cells might subject cells to confer cancer and stemness features by activation of MEK/ERK signaling, thus promoting tumor-initiating and therapy resistance in HCC. These results suggest that it may be therapeutically relevant to consider methods to enhance PRMT6 expression in HCC, in combination with use of MEK/ERK inhibitors. In a recent study, Liao et al. (2017) elegantly reported a robust system for in vivo activation of endogenous target genes through trans-epigenetic remodeling. The system relies on recruitment of Cas9 and transcriptional activation complexes to target loci by modified single-guide RNAs; and as a proof of concept, they used the technology to treat mouse models of diabetes, muscular dystrophy, and acute kidney disease (Liao et al., 2017) . This tool can be considered for use in PRMT6 gene activation in vivo in HCC patients and as a combination treatment along with use of MEK/ERK inhibitors for anti-cancer stemness targeting in HCC.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Invitrogen. Cell lines used in this study were regularly authenticated by morphological observation and tested for absence of Mycoplasma contamination. HCC and distal adjacent non-tumor liver tissues were obtained from patients undergoing hepatectomy or liver transplantation at Queen Mary Hospital, Hong Kong. Informed consent was obtained from all patients before the collection of liver specimens. Specimen collection and all experiments were approved by the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster. Samples were collected from patients who had not received any previous local or systemic treatment prior to operation. For organoid cultures, cells were isolated and cultured according to previously reported protocol (Huch et al., 2015) . Liver cells were isolated from human liver biopsies (0.5-1cm 3 ) by collagenase-accutase digestion. The different fractions were mixed and washed with cold Advanced DMEM/F12 and spun at 300-400 3 g for 5 min. The cell pellet was mixed with Matrigel (BD Biosciences) and 3,000-10,000 cells were seeded per well in a 24-well/plate. After Matrigel had solidified, culture medium was added. Culture media was based on AdDMEM/F12 (Invitrogen) supplemented with 1% N2 and 1% B27 (both from GIBCO), 1.25mM N-Acetylcysteine (Sigma), 10nM gastrin (Sigma), and the growth factors: 50ng/ml EGF (Peprotech), 10% RSPO1 conditioned media (homemade), 100ng/ml FGF10 (Peprotech), 25ng/ml HGF (Peprotech), 10mM Nicotinamide (Sigma), 5mM A83.01 (Tocris), and 10mM FSK (Tocris). For the establishment of the culture, the first 3 days after isolation, the medium was supplemented with 25ng/ml Noggin (Peprotech), 30% Wnt CM (homemade prepared), and 10mM (Y27632, Sigma Aldrich). Then, the medium was changed into a medium without Noggin, Wnt or Y27632. After 10-14 days, organoids were removed from the Matrigel, mechanically dissociated into small fragments, and transferred to fresh matrix. Passage was performed in a 1:4-1:8 split ratio once every 7-10 days for at least 6 months. HCC and distant adjacent non-tumor liver tissues used for organoid established were also obtained from patients undergoing hepatectomy or liver transplantation at Queen Mary Hospital, Hong Kong, with informed consent obtained from all patients and protocol approved by ethics committee as stated above.
Archived patient samples
Formalin-fixed paraffin-embedded primary human HCC and adjacent non-tumor liver tissue samples were obtained from HCC patients who underwent surgical resection at the Sun Yat-Sen University Cancer Centre in Guangzhou, China. Informed consent was obtained from all patients before the collection of liver specimens. Specimen collection and all experiments were approved by the Institutional Review Board of Sun Yat-Sen University. Tissue samples were collected from patients who had not received any previous local or systemic treatment prior to operation.
Animal studies
The study protocol was approved by and performed in accordance with the Committee of the Use of Live Animals in Teaching and Research at The University of Hong Kong. PRMT6 À/À mice were provided by Sté phane Richard (Neault et al., 2012) . PRMT6 À/À mice were viable, fertile and did not display any overt phenotype. WT C57BL/6J and PRMT6 À/À mice were treated with N-nitrosodiethylamine (DEN, intraperitoneal, 1mg/kg) at the age of 14 days. Starting at 8 weeks of age, carbon tetrachloride (CCl 4 , intraperitoneal, 0.2ml/kg) was administered twice weekly for an additional 14 weeks (Uehara et al., 2014) . Body weight, liver weight, number and size of tumors were measured at end point. Livers were harvested for histological analysis. Tumorigenicity was determined by subcutaneous injection into the flank of 4-to-5 week old male BALB/C nude or NOD/SCID mice. Tumor-initiating and self-renewal abilities were investigated by limiting dilution and serial transplantation assays. 4-to-6 week old male NOD/SCID mice were injected subcutaneously with either 5,000 or 10,000 cells. Tumor incidence and tumor latency were recorded. Tumor-initiating frequency was calculated using the Extreme Limiting Dilution Analysis (ELDA) software. Established xenografts were harvested and dissociated for subsequence passage to secondary mouse recipients. After tumors were detected, tumor sizes were measured every 3 days by calipers and tumor volumes were calculated as volume (cm 3 ) = L x W 2 x 0.5 with L and W representing the largest and smallest diameters, respectively. Tumors formed were harvested for histological analysis. Metastasis was assessed by orthotopically injecting into the liver of 6 week old BALB/C nude mice to observe for lung metastasis. Specifically, luciferase-labeled cells were injected into the left lobes of the livers of BALB/C nude mice. Six weeks after implantation, mice were administered with 100mg/kg D-luciferin via peritoneal injection 5 mins before bioluminescent imaging (IVIS TM 100 Imaging System, Xenogen). Livers were harvested for ex vivo imaging and histological analysis. Animals that were injected with tumor cells but showed no sign of tumor burden were generally terminated six months after tumor cell inoculation, and animals were opened up at the injection sites to confirm that there was no tumor development.
METHODS DETAILS
Reagents, kits and plasmids WT PRMT6 and catalytically inactive PRMT6 mutant (Neault et al., 2012) were provided by Stè phane Richard (McGill University, Canada). MEK inhibitor U0126 was purchased from Cell Signaling Technologies. ERK kinase assay was performed using the KinaseSTAR JNK assay kit (BioVision) where c-Jun was used as a substrate. CRAF kinase assay was purchased from Millipore (Upstate) where MEK1/2 was used as a substrate. WT and catalytically inactive PRMT6 were subcloned into Gateway entry vector pDONR201 (Invitrogen) using the forward primer 5 0 -GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGTCGCAGCCCAAGAAAA GAAAGC-3 0 and reverse primer 5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGTCCTCCATGGCAAAGTCTTTG-3 0 . FL and the truncated mutants of CRAF were cloned into Gateway vector pDONR201 by the following primers: FL: F (5 0 -GGGGACAAGTTTG TACAAAAAAGCAGGCTCCATGGAGCACATACAGGGAGCTTGGA-3 0 ), R (5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAG AAGACAGGCAGCCTCGGGGAC-3 0 ); D1 (5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGTCTTACATGAAGATGATCTGATCTCGG-3 0 ); D2 (5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGTCTTACTGGGTCCCAGATACTGGTGCC-3 0 ); D3 (5 0 -GGGGACCACTTTGTA CAAGAAAGCTGGGTCTTAAGACTCTCGCATACGACGCATA-3 0 ); D4 (5 0 -GGGG-ACCACTTTGTACAAGAAAGCTGGGTCTTAGTTG TGTGTTGTGAGGGGAACA-3 0 ); D5 (5 0 -GGGG ACCACTTTGTACAAGAAAGCTGGGTCTTAGTCATGCAAGCTCATTCCATTT-3 0 ); D6 (5 0 -GGGGACAAGT TTGTACAAAAAAGCAGGCTCCATGTGCCTTATGAAAGCACTCAAGG-3 0 ). PCR reactions were performed using the PrimeSTAR GXL kit (Takara). Gateway compatible plasmids including CMV-SFB, HA-FLAG and pMH-MBP were provided by Michael Huen (The University of Hong Kong, China). Recombination steps were accomplished with the use of Gateway and BP Clonase II and LR Clonase II (Invitrogen). WT and catalytic inactive PRMT6 were shuttled into the EZShuttle recombination cloning expression vector pEZ-Lv199 (Genecopoeia) for lentiviral-based stable overexpression. RAS was subcloned into Gateway entry vector pDONR201 (Invitrogen) using forward primer 5 0 -GGGGACAAGTTTGTACAAAAAAGCAGGCTATGACGGAATATAA GCTGGTGGT-3 0 and reverse primer 5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGTCAGGAGAGCACACACTTGC-3 0 ; and subsequently shuttled into pMH-MBP. The site-directed mutants of CRAF were constructed using the primers: R89K F (5 0 -CTCAAGG TGAAAGGCCTGCAA-3 0 ), R (5 0 -TTGCAGGCCTTTCACCTTGAG-3 0 ) and R100K F (5 0 -GCAGTGTTCAAACTTCTCCAC-3 0 ), R (5 0 -GTGGAGAAGTTTGAACACTGC-3 0 ) such that arginine-to-lysine conversions were introduced. For in vitro methylation assay, WT and site-directed mutants were subcloned into glutathione S-transferase (GST)-tag containing pGEX4t1 vector (Addgene). All DNA expression constructs were confirmed by DNA sequencing.
Flow cytometry and cell sorting
Flow cytometry analysis or flow cytometry cell sorting was conducted using PE-conjugated mouse anti-human CD133 (Miltenyi Biotec), FITC-conjugated mouse anti-human CD24 (BD Biosciences), FITC-conjugated mouse anti-human CD90 (Miltenyi Biotec) and its respective isotype control. Samples were analyzed and sorted on BD FACSCanto II and FACSAria I, respectively (BD Biosciences) with data analyzed by FlowJo (Tree Star Inc.).
Gene expression profiling
Gene expression profiling studies involving non-tumor liver (n = 50) and HCC (n = 371) tissue samples were performed analyzing the expression of PRMT6 transcripts available under Liver Hepatocellular Carcinoma (LIHC) of the TCGA Research Network and analyzed using UCSC Xena Browser.
Agilent microarray profiling cDNA microarray profiling on Agilent Human Gene Expression Array 8x60K v3 was performed as a service at Macrogen. Pathway enrichment analyses on the differentially expressed genes were conducted using Gene Set Enrichment Analysis (GSEA, Broad Institute) and Ingenuity Pathway Analysis (IPA, QIAGEN) softwares.
Quantitative real-time PCR Total RNA was extracted using RNA-IsoPlus (Takara) and cDNA was synthesized by PrimeScript RT Master Mix (Takara). qPCR was performed with EvaGreen qPCR Master Mix (ABM) and the following primers PRMT6: F (5 0 -ACGAGTGCTACTCGGACGTT-3 0 ), R (5 0 -AGTTCCGAAGGATACCCAGG-3 0 ) and b-ACTIN: F (5 0 -CATCCACGAAACTACCTTCAACTCC-3 0 ), R (5 0 -GAGCCGCCGATC CACACG-3 0 ) on an ABI Prism 7900 System (Applied Biosystems) with data analyzed using the ABI SDS v2.3 software (Applied Biosystems). Relative expression differences were calculated using the 2 -DDCt method.
Western blot and co-immunoprecipitation Protein lysates were quantified and resolved on a SDS-PAGE gel, transferred onto a PVDF membrane (Millipore) and immunoblotted with a primary antibody, followed by incubation with a secondary antibody. Antibody signal was detected using an enhanced chemiluminescence system (GE Healthcare). The following antibodies were used: PRMT6 (1:500, Abcam, ab47244) (Phalke et al., 2012) (1:1000, Cell Signaling, 9282) and b-ACTIN (1:5000, Sigma-Aldrich, A5316). For Co-IP experiments, cells were lysed by ice-cold NETN buffer (20mM Tris-HCl pH 8.0, 100mM NaCl, 1mM EDTA and 0.5% v/v NP40), and the SFB-or HA-FLAG-tagged proteins were pulled-down by streptavidin bead slurry (Amersham) and anti-FLAG M2 affinity gel (Sigma-Aldrich), respectively. The proteins were precipitated by incubation under 4 C for 3-4 hr with gentle shaking. For endogenous PRMT6 Co-IP experiments, cells were lysed by ice-cold NETN buffer and endogenous PRMT6 was pulled-down by PRMT6 antibody (5 mg/mg lysate, Bethyl Laboratories, A300-928A) and Protein A Sepharose (BioVision). The proteins were precipitated by incubation under 4 C for 16 hr methyl R2) antibody (Abcam, ab175007) or rabbit IgG control (Santa Cruz, sc-2027) . Immunoprecipitated and eluted DNA was purified with columns and amplified by qPCR with the following primers: p21 promoter region, forward, 5 0 -TGCGTTCA CAGGTGTTTCTG-3 0 and reverse, 5 0 -CACATCCCGACTCTCGTCAC-3 0 ; p27 promoter region, forward, 5 0 -ACTCGCCGTGTCAAT CATTT-3 0 and reverse, 5 0 -AACACCCCGAAAAGACGAG-3 0 ; p57 promoter region, forward, 5 0 -TCCAGCTCTCCAGCTTTTG-3 0 and reverse, 5 0 -TCCAGTCTGTTTGTGCTTGTG-3 0 .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism 5.0 and SPSS 21.0. Independent Student's t test was used to compare the mean value of two groups. Clinico-pathological significance in clinical samples was evaluated by Fisher's exact test and independent Student's t test for categorical data and continuous data, respectively. The differences in survival were calculated using the Kaplan-Meier test. Survival analysis in mouse model was performed by log-rank test. Data representative of two or more independent experiments. Bars and error represent mean ± standard deviations (SD) of replicate measurements. Statistical significance was defined as p % 0.05. *p < 0.05, **p < 0.01 and ***p < 0.001. Number of animals included per group can be found in each respective Figure. DATA AND SOFTWARE AVAILABILITY Microarray gene expression data are deposited at the NCBI GEO under the accession number GEO: GSE97931.
